Meeting
2024 ASCO Genitourinary Cancers Symposium
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
Authors
Joseph M Jacob
Department of Urology, Upstate Medical University, Syracuse, NY
Joseph M Jacob , Félix Guerrero-Ramos , Evanguelos Xylinas , Giuseppe Simone , Yair Lotan , Christopher Michael Pieczonka , Harm Arentsen , Andrea Necchi , Girish S. Kulkarni , Manish Patel , David J Cahn , Jong Kil Nam , Martin Boegemann , Shalaka Hampras , Katherine Stromberg , Jason L. Martin , Abhijit Shulka , Hussein Sweiti , Michiel Simon Van Der Heijden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Other
Clinical Trial Registration Number
NCT04640623
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 701)
DOI
10.1200/JCO.2024.42.4_suppl.701
Abstract #
701
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
First Author: Michiel Simon Van Der Heijden
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
First Author: Girish S. Kulkarni